This week’s pharma headlines highlight a shifting competitive landscape: J&J’s psoriasis pill icotrokinra challenges biologics, Novo Nordisk’s Rybelsus secures a first-in-class EU cardiovascular label, and GSK commits $30B to U.S. expansion under political pressure.